TriLink BioTechnologies and Avantor® Collaborate to Enhance Nucleic Acid Solutions Across Europe

TriLink BioTechnologies Partners with Avantor to Expand Nucleic Acid Solutions in EMEA Region TriLink BioTechnologies® (TriLink), a global leader in providing life science reagents and services, has announced a strategic partnership with Avantor® Inc. (NYSE: AVTR), a key player in…

Read MoreTriLink BioTechnologies and Avantor® Collaborate to Enhance Nucleic Acid Solutions Across Europe

Dxcover Limited Secures New Funding and Expands Leadership Team to Drive Growth

Dxcover Secures $6.2 Million in Funding to Drive Growth and Expand Cancer Diagnostics Reach Dxcover Limited, a pioneering clinical-stage diagnostics company known for its cutting-edge multiomic spectral analysis technology (MOSA-Dx™) for the early detection of solid tumor cancers, has announced…

Read MoreDxcover Limited Secures New Funding and Expands Leadership Team to Drive Growth

Inhalon Biopharma to Begin Human Trials for First Inhaled Antibody Treatment for RSV

Inhalon Biopharma Advances Breakthrough Inhaled Antibody Treatment for RSV, Targets 2026 Human Trials Inhalon Biopharma, Inc., a clinical-stage company pioneering innovative treatments for acute respiratory infections (ARI), has announced a major milestone in the development of its first-in-class inhaled antibody…

Read MoreInhalon Biopharma to Begin Human Trials for First Inhaled Antibody Treatment for RSV

Avanzanite Bioscience Proudly Names New Chief Financial Officer

Bioscience B.V., a pioneering commercial-stage specialty pharmaceutical company dedicated to advancing life-changing medicines for rare disease patients across Europe, has announced the appointment of Abdelghani (Abdel) Omari as its first-ever Chief Financial Officer (CFO). This strategic milestone strengthens the company’s…

Read MoreAvanzanite Bioscience Proudly Names New Chief Financial Officer
Subcutaneous

CHMP Recommends Subcutaneous RYBREVANT® for Advanced EGFR-Mutated NSCLC Treatment

Janssen-Cilag International NV, a subsidiary of Johnson & Johnson, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the Subcutaneous European Medicines Agency (EMA) has issued a positive recommendation for an extension of marketing authorization for…

Read MoreCHMP Recommends Subcutaneous RYBREVANT® for Advanced EGFR-Mutated NSCLC Treatment
Health Care

Health Care Marquis Who’s Who Recognizes Gail L. Lamoureux, BS, for Excellence in Health Care

Marquis Who’s Who Recognizes Gail L. Lamoureux, BS, for Excellence in Health Care Gail L. Lamoureux, BS, a dedicated and accomplished professional in the health care industry, has been honored with inclusion in Marquis Who’s Who. This Marquis prestigious recognition…

Read MoreHealth Care Marquis Who’s Who Recognizes Gail L. Lamoureux, BS, for Excellence in Health Care

Vertex Secures CASGEVY® Reimbursement Agreement for Sickle Cell Disease Treatment in England

Vertex Pharmaceuticals Announces Landmark Reimbursement Agreement with NHS England, Expanding Access to CASGEVY® for Sickle Cell Disease Patients Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has revealed a significant milestone in the fight against sickle cell disease (SCD) with the announcement of…

Read MoreVertex Secures CASGEVY® Reimbursement Agreement for Sickle Cell Disease Treatment in England

Poxel’s Partner Sumitomo Pharma Reports TWYMEEG® Sales for Q4 and FY 2024 in Japan

TWYMEEG® Sales Performance and Forecast Update Poxel’s Partner Sumitomo Pharma Reports TWYMEEG® Sales for Q4 and FY 2024 in Japan A clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic and serious diseases characterized by metabolic pathophysiology, including metabolic…

Read MorePoxel’s Partner Sumitomo Pharma Reports TWYMEEG® Sales for Q4 and FY 2024 in Japan

BrightHeart Unveils Groundbreaking AI Results at SMFM 2025 Pregnancy Meeting, Transforming Prenatal Care

BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, recently presented two groundbreaking studies at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, which took place in Aurora, Colorado, on January 30th. These presentations,…

Read MoreBrightHeart Unveils Groundbreaking AI Results at SMFM 2025 Pregnancy Meeting, Transforming Prenatal Care

KORU Medical Systems Partners on Phase III Clinical Trial for New Nephrology Drug Indication

KORU Medical Systems Announces Strategic Collaboration for Phase III Clinical Trial on Expanded Drug Indication for Rare Renal Disorder KORU Medical Systems (NASDAQ: KRMD), a prominent medical technology company focused on innovative, patient-centric large volume subcutaneous infusion solutions, has announced…

Read MoreKORU Medical Systems Partners on Phase III Clinical Trial for New Nephrology Drug Indication